Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 1/20 | 0.39 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.39 |
| ▸ | GRM5 | P41594 | 3/20 | 0.33 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 1/20 | 0.30 |
| ▸ | CNR2 | P34972 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20102572 | 0.88 | RARB (0.37) | FFAR1FFAR4CNR1CNR2 | |
| SCHEMBL20111480 | 0.83 | GRM5 (0.36) | FFAR1FFAR4GRM5 | |
| SCHEMBL20102473 | 0.80 | GPR3 (0.35) | FFAR1FFAR4 | |
| SCHEMBL7859016 | 0.70 | FFAR1 (0.47) | FFAR1FFAR4CNR1CNR2 | |
| SCHEMBL7859826 | 0.70 | FFAR1 (0.55) | FFAR1FFAR4CNR1CNR2 | |
| SCHEMBL20102594 | 0.69 | RARB (0.38) | FFAR1FFAR4 | |
| SCHEMBL13636432 | 0.69 | ALOX5 (0.38) | FFAR1FFAR4CNR1CNR2 | |
| SCHEMBL10302791 | 0.67 | FFAR1 (0.44) | FFAR1FFAR4GRM5 | |
| SCHEMBL7858585 | 0.67 | FFAR1 (0.52) | FFAR1FFAR4 | |
| SCHEMBL7858754 | 0.67 | FFAR1 (0.52) | FFAR1FFAR4CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10323187-B2 | Liquid crystal compound having biphenylene, liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2019-06-18 | — | — | US | disclosed |
| US-20180119009-A1 | LIQUID CRYSTAL COMPOUND HAVING BIPHENYLENE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2018-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180119009-A1 | LIQUID CRYSTAL COMPOUND HAVING BIPHENYLENE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | YBX1, PIEZO1, C1S | FFAR1 536/4885FFAR4 309/4885GRM5 4216/4885 |
| US-10323187-B2 | Liquid crystal compound having biphenylene, liquid crystal composition and liquid crystal display device | YBX1, PIEZO1, C1S | FFAR1 536/4885FFAR4 309/4885GRM5 4216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.